Human papilloma virus 16 type E7 protein functional antagonist peptide and encoding gene and application thereof

Abstract

The invention discloses an HPV 16 type E7 protein functional antagonist peptide and an encoding gene and an application thereof. The amino acid sequence of the HPV 16 type E7 protein functional antagonist peptide is shown in a sequence 1 in a sequence list. The HPV 16 type E7 protein is taken as the target protein, micromolecular short peptides which can be combined with the HPV 16 type E7 protein and is used for inhibiting the activity of combination between the HPV 16 type E7 protein and the pRb protein are screened to obtain a group of HPV 16 type E7 protein functional antagonist peptides with consistent sequences, and the HPV 16 type E7 protein functional antagonist peptides can be taken as the drug candidate for curing the cervical carcinoma induced by the HPV infection. The HPV 16 type E7 protein functional antagonist peptide has wide application value and broad market prospect in the preparation of the drug for curing the cervical carcinoma induced by the HPV infection.

Description

technical field [0001] The invention relates to an HPV type 16 E7 protein function antagonistic peptide and its encoding gene and application. Background technique [0002] Cervical cancer (CC) has the second highest cancer mortality among women in the world. In the past two decades, a large number of studies have been conducted on human papillomavirus (HPV) and its role in the pathogenesis of cervical cancer. It is believed that HPV infection is a necessary condition for the occurrence and development of most cervical cancers (SchiffmanMH, Brinton LA. The epidemiology of cervical carcinoma genesis. Cancer, 1995, 76:1888-1901. Cruickshank ME. The role of human papillomavirus in risk management. Gynaecol Practice, 2003, 3: 229-233.). According to reports, HPV-DNA can be detected in 99.7% of cervical cancer specimens from 22 countries (Lang J H. To receive the global challenge and opportunity for preventing cervical cancer. Chin JO bstet Gynecol, 2002, 37: 129-131. Walboomer...

AI Technical Summary

Problems solved by technology

However, the immunogenicity of peptide vaccines is weak, and there are restrictions on MHC-I molecules, so its application has certain limitations; while the safety of gene vaccines and the effect of inducing effective immune responses need to be further improved

[0005] Preventive vaccines and therapeutic vaccines need to induce effective cellular immunity and humoral immunity to play a role in the body, which has a certain timeliness, and most vaccines are weak in immunogenicity, and they need appropriate adjuvant assistance to induce the body to produce effective immunity. At the same time, due to the diversity of HPV virus subtypes, there is no report of a broad-spectrum effective vaccine against different subtypes of HPV

Images